Marketing-authorisation holder · Spain
Recordati Rare Diseases
26 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Spain
26 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 26
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CARBAGLU 200 mg COMPRIMIDOS DISPERSABLES200 mg · Comprimido dispersable | Carglumic acid | Spain | Authorised | 2003 |
| CARBAGLU 200 mg COMPRIMIDOS DISPERSABLES200 mg · Comprimido dispersable | Carglumic acid | Spain | Marketed | 2005 |
| CARBAGLU 200 mg COMPRIMIDOS DISPERSABLES200 mg · Comprimido dispersable | Carglumic acid | Spain | Marketed | 2003 |
| CYSTADANE 1 g POLVO ORAL1 g · Polvo para solución oral | Betaine | Spain | Marketed | 2007 |
| CYSTADROPS 3,8 MG/ML COLIRIO EN SOLUCION5,6 mg · Colirio en solución | Mercaptamine | Spain | Authorised | 2017 |
| CYSTAGON 150 mg CAPSULAS DURAS150 mg · Cápsula dura | Mercaptamine | Spain | Marketed | 2000 |
| CYSTAGON 50 mg CAPSULAS DURAS50 mg · Cápsula dura | Mercaptamine | Spain | Marketed | 2000 |
| ENJAYMO 50 MG/ML SOLUCION PARA PERFUSION50 mg/ml · Solución para perfusión | Sutimlimab | Spain | Authorised | 2025 |
| ISTURISA 1 mg COMPRIMIDOS RECUBIERTOS CON PELICULA1,431 mg · Comprimido recubierto con película | Osilodrostat | Spain | Marketed | 2021 |
| ISTURISA 10 mg COMPRIMIDOS RECUBIERTOS CON PELICULA14,310 mg · Comprimido recubierto con película | Osilodrostat | Spain | Marketed | 2021 |
| ISTURISA 5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA7,155 mg · Comprimido recubierto con película | Osilodrostat | Spain | Marketed | 2021 |
| NORMOSANG 25 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSION25 mg · Concentrado para solución para perfusión | Hemin | Spain | Marketed | 2000 |
| PEDEA 5 mg/ml SOLUCION INYECTABLE5 mg · Solución inyectable | Ibuprofen | Spain | Marketed | 2004 |
| SIGNIFOR 0,3 MG SOLUCION INYECTABLE0,3 mg · Solución inyectable | Pasireotide | Spain | Authorised | 2012 |
| SIGNIFOR 0,3 MG SOLUCION INYECTABLE0,3 mg · Solución inyectable | Pasireotide | Spain | Authorised | 2012 |
| SIGNIFOR 0,6 MG SOLUCION INYECTABLE0,6 mg · Solución inyectable | Pasireotide | Spain | Authorised | 2012 |
| SIGNIFOR 0,9 MG SOLUCION INYECTABLE0,9 mg · Solución inyectable | Pasireotide | Spain | Authorised | 2012 |
| SIGNIFOR 10 MG POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE13.71 mg · Polvo y disolvente para suspensión inyectable | Pasireotide | Spain | Authorised | 2018 |
| SIGNIFOR 20 MG POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE20 mg · Polvo y disolvente para suspensión inyectable | Pasireotide | Spain | Marketed | 2015 |
| SIGNIFOR 30 MG POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE41.13 mg · Polvo y disolvente para suspensión inyectable | Pasireotide | Spain | Authorised | 2018 |
| SIGNIFOR 40 MG POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE40 mg · Polvo y disolvente para suspensión inyectable | Pasireotide | Spain | Marketed | 2015 |
| SIGNIFOR 60 MG POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE60 mg · Polvo y disolvente para suspensión inyectable | Pasireotide | Spain | Marketed | 2015 |
| VEDROP 50 MG/ML EN SOLUCION ORAL50 mg · Solución oral | Tocofersolan | Spain | Marketed | 2009 |
| VEDROP 50 MG/ML EN SOLUCION ORAL50 mg · Solución oral | Tocofersolan | Spain | Marketed | 2009 |
| WILZIN 25 MG CAPSULAS DURAS25 mg · Cápsula dura | Zinc | Spain | Marketed | 2005 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 26 | 26 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.